



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/009,620	12/11/2001	Stanley J. Wiegand	REG 334-A-US	1424
7590	03/09/2006		EXAMINER	
Linda O Palladino Regeneron Pharmaceuticals Inc 777 Old Saw Mill River Road Tarrytown, NY 10591			JUNG, WILLIAM C	
		ART UNIT	PAPER NUMBER	
		3737		

DATE MAILED: 03/09/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/009,620	WIEGAND, STANLEY J.
	Examiner	Art Unit
	William Jung	3737

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on December 1, 2001.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-34 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-34 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 11022003.
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: _____.

DETAILED ACTION***Claim Rejections - 35 USC § 102***

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

2. Claims 1-9 and 11-34 are rejected under 35 U.S.C. 102(e) as being anticipated by *Li et al* (US 6,066,123).

Li et al anticipate all claimed features in claims 1-9 and 11-34.

Claims 1-3, 6-9, 11, 12, and 22-30: *Li et al* disclose a method for imaging tumor vasculature (i.e. angiogenesis) in a mammal or human, comprising a molecule capable of detecting Ang-2 nucleic acid or polypeptide coupled to an imaging agent (usually a double ligand bonding via DTPA), allowing the composition to be target specific to accumulate to a region of interest to detect the tumor vasculature via imaging the imaging agent. In addition, the method above includes coupling a therapeutic agent to the imaging agent to treat or kill tumor cells (col. 5, lines 8-32; col. 6, lines 12-28; col. 7, lines 10-61). Furthermore, *Li et al*'s method above includes materials or kit to carry out the described procedures to image and treat the patient.

Claim 4: *Li et al* disclose that the imaging method above can be applied to imaging system consisting of scintillation or gamma camera (i.e. x-ray), PET, SPECT, and MRI.

Claims 5, 13-21, and 31-34: Li et al disclose that the method above includes imaging agent may be a radionuclide, chelate, anti viral proteins, monoclonal antibody, , receptor specific polypeptide chains, mRNA, and oligonucleotide to be used in mammal , and more specifically in human (col. 4, lines 29-34; col. 5, lines 23-32).

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claim 10 is rejected under 35 U.S.C. 103(a) as being unpatentable over *Li et al* as applied to claim 6 above, and further in view of Klaveness .

Li et al substantially disclose all claimed features in claim 10. In regards to therapeutic compounds, Li et al is silent as to the therapeutic compound to treat the tumor includes from the group consisting of carboplatin, cisplatin, vincristine, methotrexate, paclitaxel, docetaxel, 5-fluorouracil, UFT, hydroxyurea, gemcitabine, vinorelbine, irinotecan, tirapazamine, and matrilysin. However, the use of these therapeutic compounds is well known in the art as demonstrated by Klaveness et al, where the therapeutic agents listed above are used with ultrasound imaging contrast agent to target the specific region of interest by tagging the contrast agent/therapeutic agent with affinity to inflamed or injured cite such as tumor vasculature as described by Li et al above. Therefore, it would have been obvious to one having an ordinary skill in the art at the time the invention was made to apply the teachings Klaveness et al's therapeutic agent with Li et al's method to achieve the claimed invention.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to William Jung, Ph.D. whose telephone number is 571-272-4739. The examiner can normally be reached on Mon-Fri 8:30 AM to 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 571-272-4956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

WJC

March 5, 2006


BRIAN L. CASLER
SUPERVISORY PATENT EXAMINER
TFC
3700